Hero

News & Events

Mestag in the News
BioCentury Article: Mestag: Attacking Tumors from Within

Fierce Biotech: Merck & Co. signs $1.9B deal with Mestag to explore fibroblast therapies for inflammation

Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform

December 9, 2024

Mestag Therapeutics Expands Leadership Team and Appoints Head of Development and General Counsel

November 13, 2024

Mestag Therapeutics Announces License and Research Collaboration with MSD to Identify Novel Targets for Inflammatory Diseases

October 8, 2024

Mestag Therapeutics Awarded Significant Grant from Innovate UK’s Prestigious Cancer Therapeutics Program to Accelerate the Path to the Clinic for MST-0300

August 28, 2024

Mestag Presents Preclinical Data at AACR on its M300 Program, a Conditionally Active LTBR Agonist Designed to Induce Tertiary Lymphoid Structures in Tumors

View All Press Releases

Longwood Healthcare Leaders – San Francisco, CA

M&A and Deal-Making Landscape

January 11, 2025 | 2:30 pm PT

Conference Website

J.P. Morgan Healthcare Conference – San Francisco, CA

January 13-16, 2025

Contact Us to Connect

Crohns & Colitis Congress – San Francisco, CA

February 6-8, 2025

Conference Website

ECCO – Berlin, Germany

February 19-22, 2025

Conference Website

Keystone Symposium – Hannover, Germany

Myeloid Cells: Roles in Different Tissue Microenvironments

March 3-6, 2025

Conference Website

View All Events & Presentations